trending Market Intelligence /marketintelligence/en/news-insights/trending/qswoNJPX_9zs7KAr4qAyZg2 content esgSubNav
In This List

FibroGen files for US approval of anemia drug Evrenzo

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


FibroGen files for US approval of anemia drug Evrenzo

FibroGen Inc. filed an application seeking U.S. approval of its anemia drug Evrenzo, or roxadustat, for patients with chronic kidney disease.

Evrenzo is already approved in Japan for dialysis-dependent patients and in China for both non-dialysis-dependent and dialysis-dependent patients.

The San Francisco-based biotechnology company's new drug application with the U.S. Food and Drug Administration is based on results from 15 phase 3 trials — including Olympus, Andes, Alps, Himalayas, Sierras and Rockies — that evaluated Evrenzo's efficacy and safety in about 10,000 patients globally.

Low levels of hemoglobin, an oxygen-carrying protein in red blood cells, and insufficient red blood cells can lead to anemia, a potentially life-threatening condition common in patients with chronic kidney disease.

FibroGen is collaborating with Britain's AstraZeneca PLC to commercialize roxadustat for the treatment of anemia in the U.S. and certain other geographies.